Moreover, high-quality evidence now suggests that SGLT-2 inhibitors reduce rates of hospitalization for heart failure and ameliorate progression of diabetic kidney disease, and this is also taken into account when making treatment choices for patients with these comorbidities. Here, SLC5A2 is linked to heart failure.